NHS hearing instrument sales continue to rise in Q2
BIHIMA has released Q2 data on hearing technology market figures for 2024, revealing annual growth for NHS sales but a slight drop for private hearing instruments.
- NHS sales up 32% from Q2 2023 (with an increase of 3.6% over Q1 2024)
- Private product sales have declined 1.6% compared to Q2 2023 and 9.4%% on Q1 2024
- Sales of rechargeable (non-NHS) hearing instruments continue to edge upwards
BIHIMA – the British Irish Hearing Instrument Manufacturers Association – has released the latest Q2 2024 data on hearing instrument usage in the UK and the Republic of Ireland (ROI), showing a substantial increase for NHS sales from the same period last year.
Speaking about the data, Paul Surridge, BIHIMA Chairman, said: “We saw a strong start to sales in the first quarter of 2024 and despite a recent drop in private sales, it’s promising to see hearing instrument acquisition continue to rise within NHS settings. We hope to see continued growth as the year progresses, especially with the new Government planning to improve free access to healthcare.”
Sales in ROI experienced a plateau in overall volumes, with almost no change (-0.3%) in comparison to the preceding year and -6% over Q1 2024. Rechargeable product sales continued to creep upwards both in ROI and the UK.
Paul continued, “There are several advantages of rechargeable hearing instruments, so we aren’t surprised to see these product sales on the rise. We’re interested to see how these sales progress throughout the year and whether this will translate to more hearing instrument brands placing greater emphasis on rechargeable products.”